Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00287885|
Recruitment Status : Completed
First Posted : February 7, 2006
Last Update Posted : November 29, 2017
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Docetaxel may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving daily doses of docetaxel may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel in treating patients with refractory or recurrent advanced gynecologic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Peritoneal Cavity Cancer Sarcoma Vaginal Cancer Vulvar Cancer||Drug: docetaxel||Phase 1|
- Determine the maximum tolerated dose of metronomic docetaxel in patients with progressive or recurrent gynecologic cancer.
- Determine the response rate in patients treated with this drug.
- Determine the pharmacokinetics associated with this drug in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive docetaxel intravenously (IV) over 1-2 minutes daily for up to 6 months in the absence of unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed every 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
Experimental: Metronomic Docetaxel
Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
Other Name: Taxotere
- Maximum Tolerated Dose [ Time Frame: Up to 180 Days ]Determine the maximum tolerated dose of metronomic docetaxel in patients with progressive or recurrent gynecologic cancer
- Response to Treatment [ Time Frame: Up to 180 Days ]Determine the response rate in patients treated with this drug.
- Pharmacokinetics [ Time Frame: Day 1 through Day 5 ]Determine the pharmacokinetics associated with this drug in these patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00287885
|Study Chair:||Levi S. Downs, MD||Masonic Cancer Center, University of Minnesota|